{"name":"Kyle Greenway","slug":"kyle-greenway","ticker":"","exchange":"","domain":"","description":"Kyle Greenway is a biotechnology company focused on the development of psilocybin-based therapies for various medical conditions. The company is currently in Phase 2 clinical trials for its lead product, Psilocybin 25mg, which aims to address unmet medical needs in mental health.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBqOWZGVTBJRWlnLUtRVDhBU21WdFE1LUlOb2VoU2Z3UFBocEtucERJSmFMaHNienRFZTJiUDRvaUNBX1l4TGZ4VXRfQnk5Wm0xM19hR1BrOHFlam5RdXhv?oc=5","date":"2025-06-03","type":"trial","source":"Nature","summary":"An international Delphi consensus for reporting of setting in psychedelic clinical trials - Nature","headline":"An international Delphi consensus for reporting of setting in psychedelic clinical trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPRDRnOGFoU0RSeWRydjdWM1BTRnF0M3lwSGNWU0xvTGVRb3AyYmJaRnFnZm9XeEIxNkN4TjBzVUpzaGNIR1JLWHRHdUVFQVlkbHNYWk5rcHFoNkJDUm9QRm9PY191RHlQZko4cHZsZXJ1MlFRWF8tT3BPRE56UzZ1Wk1ibTZRS0lZNG1Jd3Y4Rm5JUQ?oc=5","date":"2024-01-31","type":"pipeline","source":"Frontiers","summary":"The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression - Frontiers","headline":"The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNZHl1bzlITzFCWkxncDA1em1XU1k0aVhNbzlDM3c3YU5nM2htb3ZwM0pYSEpWR2JDN3NjczRfVV9IdW5zdGhIZER0dkp1OV9sQWx0Y25rYlBLVEdjZGR5Z3lZVXMyb045RVItbkktdnJwaFlvWHFoSXBTOUVyZGNBQkF0bmZ6a080LWxTNHp0cWl5M0ZKRWg2RWkzeG1LRUk?oc=5","date":"2023-07-12","type":"pipeline","source":"Greenway Magazine","summary":"Revenant: Kyle Turley discusses reclaiming life through cannabis - Greenway Magazine","headline":"Revenant: Kyle Turley discusses reclaiming life through cannabis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}